About this Journal Submit a Manuscript Table of Contents
Journal of Obesity
Volume 2011 (2011), Article ID 482021, 5 pages
http://dx.doi.org/10.1155/2011/482021
Case Report

Refsum's Disease—Use of the Intestinal Lipase Inhibitor, Orlistat, as a Novel Therapeutic Approach to a Complex Disorder

1Department of Clinical Biochemistry, Royal Prince Alfred Hospital, Sydney, Camperdown, NSW 2050, Australia
2Department of Medicine, University of Sydney, NSW 2006, Australia
3Department of Biochemistry, John Hunter Hospital, Newcastle, NSW 2305, Australia
4National Referral Laboratory for Lysosomal, Peroxisomal and Related Genetic Disorders, SA Pathology at The Women's and Children's Hospital, North Adelaide, SA 5006, Australia
5School of Molecular and Biomedical Science, University of Adelaide, Adelaide, SA 5005, Australia

Received 12 May 2010; Accepted 12 July 2010

Academic Editor: S. B. Heymsfield

Copyright © 2011 Nimalie J. Perera et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to Cite this Article

Nimalie J. Perera, Barry Lewis, Huy Tran, Michael Fietz, and David R. Sullivan, “Refsum's Disease—Use of the Intestinal Lipase Inhibitor, Orlistat, as a Novel Therapeutic Approach to a Complex Disorder,” Journal of Obesity, vol. 2011, Article ID 482021, 5 pages, 2011. doi:10.1155/2011/482021